

**PRIMARY HPV SCREENING** This is a HR-HPV test specified by the FDA for Primary HPV Screening in patients 25 years and older that reflexes to a PAP test if the HPV test is positive.

As part of its testing in women's health, TriCore offers Primary HPV Screening. Guidelines for Primary HPV Screening are available from the professional societies of the American Society of Colposcopy and Cervical Pathology (ASCCP | [www.asccp.org](http://www.asccp.org)), the Society of Gynecologic Oncology (SGO | [www.sgo.org](http://www.sgo.org)), and the American Cancer Society (ACS | [www.cancer.org](http://www.cancer.org)).

Women meeting the following requirements can be offered Primary HPV testing:

- Patient must be 25 years or older.
- Specimen must be from a cervical specimen source.

Specimens for this test can be collected in ThinPrep collection media (PreservCyt) or SurePath collection media.

TriCore clients may select Primary HPV Screening from the test options on TriCore's Women's health requisition form using the test order code PRIHPV. To distinguish this test from other Pap tests with HR-HPV (co-testing and reflex HPV testing), the Primary HPV Screening test option is found under Additional Tests on the requisition.

For all high risk HPV testing (HR-HPV), TriCore utilizes the Roche Cobas 4800 HPV test.

With a test selection of Primary HPV Screening, the ASCCP guidelines algorithm will be used as follows:

- 1. ALL HPV-POSITIVE PRIMARY SCREENING RESULTS, REGARDLESS OF HPV GENOTYPE (HPV16, HPV 18, HIGH-RISK-HPV, NOT HPV 16 OR HPV 18):** Specimens will receive automatic reflex Pap testing. This does not require a separate reflex test order or request of a separate Pap test.
- 2. NEGATIVE FOR ALL HIGH RISK-HPV TYPES:** No further testing on this specimen will be performed. Patients may continue their routine screening.

**ADDITIONAL GUIDANCE:** For follow-up of Primary High-Risk HPV Screening results, please refer to guidelines recommended by the American Society of Colposcopy and Cervical Pathology (ASCCP).

Final test results for Primary HPV Screening will be reported as is currently done for all other HPV testing. Results for reflex Pap tests from #1 above are reported in a separate Gyn Cytology (Pap) report.

For any questions, please contact TriCore's Medical Director - Cytopathology, Dr. Nancy Joste or Dr. Whitney Winham at 505.938.8800 or TriCore's Medical Director - Infectious Disease, Dr. Karissa Culbreath at 505.938.8461.

## REFERENCES

Perkins RB, Guido, RS, Castle, PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24:102-131. <https://journals.lww.com/jlgttd/pages/articleviewer.aspx?year=2020 &issue=04000&article=00003&type=Fulltext&sessionEnd=true>

Fontham ETH, Wolf AMD, Church TK, et al. Cervical Cancer Screening for Individuals at Average Risk: 2020 Guidelines Update from the ASC. Ca Cancer J Clin 2020; 0: 1-26